Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma

Basit Öğe Kaydı
dc.authoridKucukarda, Ahmet/0000-0001-7399-2360
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorGokmen, Ivo
dc.contributor.authorOzcan, Erkan
dc.contributor.authorPeker, Pinar
dc.contributor.authorAkgul, Fahri
dc.contributor.authorCicin, Irfan
dc.date.accessioned2024-06-12T10:52:45Z
dc.date.available2024-06-12T10:52:45Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction: The case of a patient who developed recurrent delayed immune-related pneumonitis (checkpoint inhibitor pneumonitis [CIP]) after immune checkpoint inhibitor (ICI) therapy for advanced osteosarcoma treatment is presented. Case summary: A 25-year-old female patient with metastatic osteosarcoma was treated with atezolizumab. Grade 2 pneumonitis developed three times in the first two years. Treatment was discontinued after recovery from the last episode of pneumonitis, which was complicated with secondary spontaneous pneumothorax. 2 years after discontinuation of immunotherapy, the patient again developed CIP. Pneumonitis symptoms were regressed with oral steroid therapy during follow-up and a stable disease response continued. Conclusion: Immunotherapy can cause recurrent CIP at any time during the treatment period or after discontinuation of treatment. Plain language summary Immune checkpoint inhibitors have been used in many types of cancer because they cause prolonged tumor responses. However, new side effects associated with these drugs have been identified. Pneumonia of the lung tissue may occur and recur during the use of these drugs or after their discontinuation. Patients with newly developing pulmonary symptoms during follow-up should be carefully monitored for this side effect.en_US
dc.identifier.doi10.2217/imt-2021-0275
dc.identifier.endpage399en_US
dc.identifier.issn1750-743X
dc.identifier.issn1750-7448
dc.identifier.issue6en_US
dc.identifier.pmid35152716en_US
dc.identifier.scopus2-s2.0-85126152467en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage395en_US
dc.identifier.urihttps://doi.org/10.2217/imt-2021-0275
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18814
dc.identifier.volume14en_US
dc.identifier.wosWOS:000754671200001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofImmunotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAtezolizumaben_US
dc.subjectDelayed Immune-Related Adverse Eventsen_US
dc.subjectImmune-Checkpoint Inhibitorsen_US
dc.subjectImmunotherapyen_US
dc.subjectRecurrent Pneumonitisen_US
dc.subjectAdverse Eventsen_US
dc.titleRecurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu